All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Zai Lab's TIVDAK (tisotumab vedotin) approved in Hong Kong for recurrent/metastatic cervical cancer following chemotherapy
Antibody-drug conjugate, cancer, gynecological cancer, cervical cancer, metastatic disease, tissue factor target - Read more

THE GOOD
Business Development & Partnerships

Radiance Biopharma, Novatim Immune Therapeutics partner on bispecific ADC, $15M upfront plus $1.15B in milestones
Licensing deal, oncology, antibody-drug conjugate, milestone payments, global, R&D - Read more

Amgen partners with Veeva Systems to improve clinical trials using Veeva's technology platform
Clinical trial collaboration, technology partnership, clinical operations, data analytics, R&D - Read more

Zenas, Royalty Pharma partner on autoimmune drug obexelimab in $300M deal with $75M upfront payment
Licensing deal, autoimmune, milestone payments, commercialization, antibody, rare disease - Read more

eXmoor Pharma, Anthony Nolan partner to integrate donor sourcing and GMP manufacturing for cell therapy developers
Strategic partnership, cell therapy, manufacturing agreement, clinical development, donor services - Read more

Roche's Genentech partners with OMass Therapeutics for IBD program, $20M upfront plus $400M+ in milestones
Licensing deal, inflammatory bowel disease, small molecule, milestone payments, drug discovery, preclinical - Read more

Arrowhead, Novartis partner on siRNA Parkinson's program; $200M upfront, potential $2B in milestones
Licensing deal, neurological, siRNA, Parkinson's disease, milestone payments, R&D - Read more

Servier, IDEAYA partner on eye cancer drug darovasertib; $210M upfront, up to $530M total
Licensing deal, rare disease, oncology, milestone payments, global, small molecule - Read more

Vertex partners with Enlaza to develop autoimmune therapies, potential $2B+ deal with $45M upfront
Research collaboration, autoimmune disease, small molecule, gene therapy, milestone payments, equity investment - Read more

LOTTE BIOLOGICS partners with undisclosed US biopharma for late-stage manufacturing through 2030
Manufacturing agreement, contract manufacturing, biopharmaceutical, commercial supply, late-stage partnership - Read more

PRESENTED BY YOU?
Get the attention of 2200+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

✅ More Good News ✅

THE GOOD
Clinical Trials

United's Tyvaso shows Ph3 success in idiopathic pulmonary fibrosis, meeting primary endpoint in Teton-2 trial
Small molecule, respiratory disease, pulmonary vasodilator, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, inhaled therapy - Read more

Upstream Bio's anti-TSLP antibody verekitug meets Ph2 endpoints for chronic rhinosinusitis with nasal polyps
Antibody, autoimmune, monoclonal antibody, chronic rhinosinusitis, nasal polyps, TSLP receptor - Read more

Merck & Co.'s oral PCSK9 inhibitor enlicitide scores third Ph3 win in hyperlipidemia, advancing toward regulatory submission
Small molecule, cardiovascular, PCSK9 inhibitor, hyperlipidemia, oral delivery, cholesterol-lowering - Read more

Ionis' Tryngolza hits Ph3 goals for severe hypertriglyceridemia, shows reduction in triglycerides and pancreatitis episodes
Antisense oligonucleotide, metabolic, lipid-lowering, hypertriglyceridemia, pancreatitis - Read more

THE GOOD
Company Launches

Corsera Health launches with $50M to advance RNAi cardiovascular drug, AI prediction platform, aiming for once-yearly preventative therapy
Read more

THE GOOD
Fundraises

CHARM Therapeutics raises $80M Series B, developing AI-designed menin inhibitor for AML
Oncology, AI/ML platform, small molecule, AML, drug discovery, preclinical - Read more

THE GOOD
Investments

Amgen commits $600M to build advanced R&D facility in California, creating hundreds of jobs
Biotechnology, infrastructure investment, operational, strategic, financial - Read more

THE GOOD
Mergers & Acquisitions

SeqOne acquires Congenica, creating world's largest clinical genomics software company to accelerate rare disease diagnosis
Genomic analysis software, rare disease, oncology, strategic acquisition, digital health - Read more

THE GOOD
Strategic Plans

Editas nominates EDIT-401 as lead candidate for high cholesterol gene editing therapy, aiming for 90% LDL reduction
Gene editing, cardiovascular, strategic, pipeline development, financial - Read more

THE BAD
Clinical Trials

Zymeworks discontinues Ph1 mesothelin T-cell engager ZW171 for ovarian and non-small cell lung cancers
Antibody, cancer, T-cell engager, non-small cell lung cancer, immunotherapy, mesothelin target - Read more

Eli Lilly terminates two Ph2 trials of naperiglipron (GLP-1 agonist) for obesity, continues third mid-stage study
Small molecule, metabolic, GLP-1 receptor agonist, obesity, type 2 diabetes, weight loss - Read more

THE BAD
Layoffs

Novartis cutting 58 medical affairs jobs in New Jersey amid ongoing efficiency restructuring
Operational, cost reduction, cardiovascular, oncology, strategic restructuring - Read more

THE UGLY
Politics & Policy

HHS removes outspoken vaccine expert Paul Offit from FDA advisory committee amid Kennedy's leadership controversies
Vaccine policy, infectious disease, regulatory, political, operational - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here